All In Biotech

NDA 021140 · Kenvue Brands

Imodium Multi-Symptom Relief

Loperamide Hydrochloride, Simethicone · Oral

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Nov 30, 2000

Approved uses

2

Original approval plus efficacy supplements

Registered trials

97

20 Phase 3, 11 recruiting

FAERS reports

32,268

18,867 serious, 2,549 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 29, 2026.

Uses relieves symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • IMODIUM MULTI-SYMPTOM RELIEF · LOPERAMIDE HYDROCHLORIDE 2MG; SIMETHICONE 125MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Loperamide" as an intervention, any sponsor and status, largest first.

All 97 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6,587
  • drug ineffective3,174
  • nausea3,134
  • fatigue2,654
  • off label use2,287
  • vomiting2,148
  • constipation1,816
  • weight decreased1,538
  • incorrect dose administered1,429
  • headache1,398
  • dyspnoea1,388
  • abdominal pain1,362

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004255
2005303
2006321
2007354
2008410
2009424
2010473
2011671
2012874
2013770
2014970
20154,439
20161,910
20172,173
20182,311
20191,989
20202,173
20212,035
20222,152
20232,354
20241,928
20251,862
20261,114

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 306 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.